PRAME was homogenously expressed across all skin, endometrial, ovarian, breast, and lung cancer types tested (Fig. 1a), suggesting that a PRAME-targeted therapy has the potential to act on most malignant cells within the tumor microenvironment. The gene discussed is PRAME; the disease is lung cancer.